Ca v 3.2 T-channel plays a pivotal role in inducing calcineurin/nuclear factor of activated T cell (NFAT) signaling during cardiac hypertrophy. Because calcineurin/NFAT signaling is induced early after pressure overload, we hypothesized that Ca v 3.2 is induced by an early signal. Our aim is to investigate when and how Ca v 3.2 is induced during cardiac hypertrophy.
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INTRODUCTION
Adult hearts undergo hypertrophic remodeling as a compensatory response to various stimulations, including exercise, pregnancy, chronic hypertension, myocardial infarction and other heart diseases 1 . Although considered a beneficial response in the beginning, prolonged hypertrophy will progress into heart failure under pathological conditions.
Hallmarks of cardiac hypertrophy include increased cell size, actin reorganization, increased protein synthesis and fetal gene re-expression. The fetal genes re-expressed in hypertrophic hearts include atrial and brain natriuretic peptide (ANP and BNP, respectively), fetal isoforms of contractile proteins (α-skeletal actin and β-myosin heavy chain), and ion channels typically expressed in the fetal heart, such as hyperpolarization-activated cyclic nucleotide-gated channel and T-type calcium channel (T-channel) 2 . Although the transcriptional regulation of ANP and BNP during cardiac hypertrophy was well studied, the regulation of other fetal genes including T-channel is still unclear.
Two types of voltage-gated Ca 2+ channels are present in hearts, namely L-and T-channel. Ca 2+ current through the L-channel plays a key role in excitation-contraction coupling and Ca 2+ current through the T-channel is thought to be involved in the atrioventricular conduction 7, 8 . In contrast, mice lacking Ca v 3.2 showed normal heart rate 9 .
In myocardium, T-channel is normally expressed in fetal and absent in adult ventricles, but re-expressed in adult ventricular myocytes in different cardiac myopathy models [10] [11] [12] .
T-current is found induced along with Ca v 3.1 or Ca v 3.2 upregulation in different models of cardiac dysfunction [11] [12] [13] [14] [15] ; however, the roles of the genes in the progression of cardiac hypertrophy differ. Cardiac-specific overexpression of Ca v 3.1 attenuated cardiac hypertrophy through a nitric oxide synthase 3-dependent signaling mechanism 15 , whereas Ca v 3.2 deletion attenuated pressure overload-induced cardiac hypertrophy by reducing the calcineurin/ NFAT signaling pathway 12 . These studies suggest that Ca v 3.1 is anti-hypertrophic and Ca v 3.2 is pro-hypertrophic in response to pressure overload stress.
Ca v 3.2 T-channel is required for angiotensin II-and pressure overload-induced cardiac hypertrophy in mice 12 . The re-expression of ventricular T-channels observed in wild-type hypertrophic hearts was absent in Ca v 3.2-null mice, which suggests that re-expressed T-channel is encoded by Ca v 3.2. Moreover, pharmacological blockade of T-channel reduced arrhythmias during dilated cardiomyopathy and prevented sudden death due to myocardial infarction in mice 16 . The mouse model of dilated cardiomyopathy in their study involved transgenic mice with a cardiac-specific dominant-negative form of neuron-restrictive silencer factor (dnNRSF-Tg) showing cardiac upregulation of Ca v 3.2 but not Ca v 3.1 17 . These studies suggest that targeting Ca v 3.2 could be beneficial for heart
The injection procedure was modified from method described previously [19] [20] [21] . In brief, 8-to 10-week-old mice (C57BL/6J) were anesthetized (vaporized 1% isoflurane) and pectoralis muscle was cut and flipped up to visualize the beating heart underneath intercostal muscle. DNA-saline solution (40 µL containing 5 µg testing firefly luciferase and 5 µg control Renilla luciferase) was injected through intercostal muscle into the left ventricle at 3-4 sites using a 27-gauge needle. After injection, the pectoralis minor muscle was adhered to the oblique muscle by use of tissue glue. Immediately after gene transfer, mice underwent TAB or sham operation.
Animal model of cardiac hypertrophy
Eight-week-old adult male mice (C57BL/6J) weighing 20-25g were anesthetized (vaporized 1% isoflurane) and subjected to pressure overload by transverse aortic banding (TAB) as described 12 .
Establishing the stable line of H9c2
RNAi reagents were from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan. The vectors (pLKO TRC005) carrying the short hairpin RNA (shRNA) with the target sequence of Egr1 (Egr1 KD) 5'-CACTCCACTATCCACTATTAA-3' were electroporated into H9c2 cells. After recovery overnight, cells were cultured and maintained with complete medium with 0.125 µg/mL puromycine (Sigma). The control KD construct carried the shRNA targeting the EGFP sequence 5'-CCTACGGCGTGCAGTGCTTCA-3'.
Electrophoresis mobility shift assay (EMSA)
Binding reactions involved use of a digoxigenin (DIG)-labeled probe containing the sequence from -81 to -41 of the mouse Ca v 3.2 promoter 
Chromatin immunoprecipitation (ChIP) assay
Transfected H9c2 cells were crosslinked and chromatins were prepared as the instruction of the Pierce agarose ChIP kit (Thermo). For immuno-precipitation, 10 µL anti-Flag M2 affinity gel (Sigma) or an equal amount of murine IgG was added. After purification, DNA was amplified by real-time quantitative PCR with primer sequences corresponding to the rat Ca v 3.2 promoter region (-180 to -1, 5' primer: 5'-gatgtcttgggatagcttacgt-3'; 3' primer: 5'-aggaaacttcggagtgagc-3').
In situ hybridization
The fragment of Ca v 3.2 3'-UTR was cloned from a mouse testis cDNA pool with the primer sequences forward with a BamHI site, 
Immunostaining
Immunofluoresence staining for Egr1 was conducted using anti-Egr1 antibody (1:250, SC-110, Santa Cruz) and Alexa-594 conjugated anti-rabbit IgG was used as the secondary antibody.
Image capture and analysis
Images of in situ hybridization and immunostaining were obtained by use of the digital camera attached to an Olympus upright microscope. To measure cell size, H9c2 cells were incubated with 2.5 µM CFSE (Invitrogen) following the manufacturer's instructions. After fixation with 4% paraformaldehyde, DAPI was used to stain nuclei. Images were taken by use of High Content Screening (Molecular Devices).
Statistical analysis
Data are expressed as mean±SD. Statistical comparisons were performed with independent-samples Mann-Whitney Rank Sum Test for two sample groups, one-way ANOVA for more than two sample groups and followed by Dunnett's test for the post-hoc analysis with control groups in different experiment. A P<0.05 was considered statistically significant.
RESULTS
Proximal 3.5 kb of the mouse Ca v 3.2 5'-flanking sequence (FS) carries the regulatory elements for Ca v 3.2 gene expression in hearts
The genomic sequences of Ca v 3.2 from different species were aligned by use of the online ECR browser to obtain the conserved region 22 Figure 1D ).
The transcription factor (TF) early growth response 1 (Egr1) induced Ca v 3.2 expression and its putative binding site Ca v 3.2-81~-41 was the TAB responding element
To identify the TAB-responding element within Ca v 3.2-3500, we performed in vivo gene transfer in mouse hearts as described previously 19, 21 To determine the potential TFs that regulate Ca v 3.2 expression, we searched the putative TF binding sites on Ca v 3.2-420 using TFSEARCH 23 . Ca v 3.2-420 contains TF binding sites for E2F, nuclear factor-kB (NFkB), CP2, heat shock factor (HSF), Sp1, early growth response 1 (Egr1) and GATAs ( Figure 2B ). Ca v 3.2-420-Luc constructs with individual deletion in each predicted binding site were generated and expressed in HL-1 cells. Compared to Ca v 3.2-420-Luc, deletion constructs contained the binding sites for NFkB, Sp1, Egr1, and HSF significantly reduced promoter activity (Supplemental Figure 4 ).
We coexpressed these TFs individually with Ca v 3.2-3500-Luc to test their ability to induce luciferase activity. Egr1 was the only TF that could induce Ca v 3.2-3500 luciferase activity in a dose-dependent manner ( Figure 2C ). Furthermore, overexpression of Egr1 could upregulate endogenous Ca v 3.2 mRNA level by 1.57±0.07-fold in a cardiac-derived cell line, H9c2 ( Figure 2D ). These results suggest that Egr1 enhances Ca v 3.2 transcription. We also generated a reporter construct lacking the predicted Egr1 binding sites (Ca v 3.2-420 ∆ ∆ ∆ ∆ -81~-41-Luc) and showed that this construct could not respond to TAB in vivo (Figure 2A) .
These results suggest that the Egr1 putative binding site Ca v 3.2-81~-41 is the TAB-responding element.
Egr1 bound to the TAB-responding element (Ca v 3.2-81~-41)
To confirm the interaction between Egr1 and the TAB-responding element, we used EMSA with a DIG-labeled oligonucleotide (Ca v 3.2-81~-41) as a probe. Lysates from Flag-Egr1-but not Flag-transfected cells showed 3 shifted bands (lanes 2 and 3 in Figure   3A ). The shifted bands a and c completely disappeared in the presence of excess unlabeled wild-type probe (lane 8 in Figure 3A ). Thus, only bands a and c were specific were used (m1 and m3) (lanes 4,5,7 in Figure 3A ). In the presence of cold competitor with mutation in BS2 (m2), the shifted bands a and c were reduced but not completely disappeared (lane 6 in Figure 3A ). The m2 partially abolished the competition ability of the cold probe; therefore some hot probe with normal sequence can still form the complex with Egr1. These results suggest that all 3 putative Egr1 binding sites can be recognized by Egr1 and the BS2 binds Egr1 better than BS1 and BS3.
To demonstrate that Egr1 binds to the Ca v 3. 
Egr1 is required to induce Ca v 3.2 gene expression during cardiac hypertrophy
Because the luciferase activity of Tg(Ca v 3.2-3500-Luc) can be induced as early as 3 days after TAB ( Figure 1C) , we should be able to detect the expression of Egr1 early after TAB if Egr1 is involved in regulation of Ca v 3.2 during cardiac hypertrophy. We examined the protein level of Egr1 in mouse left ventricles after surgery and found that Egr1 was significantly increased after TAB as compared with sham operation (Figure 4A and B) . The expression of Ca v 3.2 mRNA was also induced (1.33±0.08-fold) 3 day after TAB ( Figure 4C ).
To confirm our hypothesis that upregulated Egr1 induces Ca v 3.2 in the progression of the pressure overload, the expression pattern of Ca v 3.2 and Egr1 were examined by in situ hybridization and immunostaining in adjacent slides, respectively. We confirmed the specificity of the Ca v 3.2 probe by no positive signals in the TAB Ca v 3.2-knockout (KO) heart.
We detected increased mRNA expression of Ca v 3.2 in TAB-but not sham-operated hearts 3 days after TAB (upper panels, Figure 4D ). Interestingly, induced Ca v 3.2 was not observed in every myocyte but rather in a mosaic pattern. Egr1 was also not expressed in every myocyte (lower panels, Figure 4D ) Figure 5F ). Thus, we concluded that the upregulation of Ca v 3.2 expression by phenylephrine requires Egr1.
Ca v 3.2 is an important effector of Egr1 contributing to the progression of cardiac hypertrophy
Egr1 is essential for the progression of cardiac hypertrophy because Egr1 KO mice showed attenuated cardiac hypertrophy induced by the pressure overload 21 24, 25 . PE significantly increased the cell surface area in control but not Egr1 KD cells ( Figure 6A and B) . This finding verified the importance of Egr1 in the cardiac hypertrophy. More importantly, overexpression of Ca v 3.2 in Egr1 KD cells restored the PE-induced hypertrophy ( Figure 6A and B) . The finding suggests that Ca v 3.2 plays a vital role in Egr1-mediated cardiac hypertrophy. precedes morphological changes of hearts with cardiac hypertrophy (Figure 1 and 4) .
DISCUSSION
Combined with our previous findings of blunted angiotensin II-and pressure overload-induced cardiac hypertrophy in Ca v 3.2-null mice 12 , these results suggest that early induced Ca v 3.2 is required for the development of cardiac hypertrophy.
Egr1 is an immediate early gene rapidly responding to different stimulations in various cells including cardiac myocytes 26, 27 . The mRNA of Egr1 can be induced early by hypertrophy-inducing hormones such as endothelin 1, angiotensin II and PE in NRVMs, neonatal rat cardiac fibroblasts, isolated heart tissues or mice [26] [27] [28] [29] [30] [31] [32] . Previously, overexpression of Egr1 specific repressor NGF1A-binding protein (NAB1) or deletion of Egr1 was shown to blunt pathological cardiac hypertrophy induced by pressure overload or adrenergic stimulation 21 . These studies demonstrate that Egr1 is an important regulator of pathological cardiac hypertrophy. However, the downstream mediator of Egr1 contributing to the regulation of pathological cardiac hypertrophy is not completely understood. Our results showed that Egr1 was upregulated in the left ventricles at the day 3 after TAB surgery ( Figure 4A and B) . At the same time, Ca v 3.2 mRNA was induced in most of Egr1-upregulated cardiomycytes ( Figure 4C and D) . Our results showed that PE-induced Egr1 and Ca v 3.2 were blunted by Egr1 knockdown ( Figure 5 ). Egr1 knockdown also blunted the PE-induced cellular hypertrophy in H9c2 cells and this phenomenon could be rescued by the overexpression of Ca v 3.2 ( Figure 6 ). Taken together, these results suggest that Ca v 3.2 is an important downstream target of Egr1 mediating pathological cardiac hypertrophy.
Egr1 was recently shown to bind to the region between -1426 to -1188 bp upstream of rat Ca v 3.2 and induce the expression of Ca v 3.2 in neuronal cells 33 . The corresponding region of rat Ca v 3.2 -1426 to -1188 bp is -850 to -612 bp in mouse Ca v 3.2 and the sequence similarity of this region between rat and mouse is 89% (Supplemental Figure 5 ). In this region, one conserved Egr1 binding site was predicted in both rat and mouse genomes and an additional Egr1 binding site was present in the rat genome. Interestingly, TAB-induced luciferase activity did not differ between Ca v 3.2-420 and Ca v 3.2-1000 reporter constructs in mouse hearts (Figure 2A ). It suggests that the region between -1000 to -420 bp of mouse gene expression.
In addition to Egr1, the transcription factors Sp1, HSF and NFkB are potential For example, coactivator-associated arginine methyltransferase (CARM1/PRMT4) directly binds to NF-kB subunit p65 and synergistically activate NF-kB target genes through histone H3-R17 methylation 34 . CARM1 is required for some NF-kB target gene expression, because a subset of NF-kB dependent gene expression was impaired in CARM1 knock out cells 35 . Therefore, solely expression of Sp1, HSF, and NFkB may not be enough to induce 
